Lactobacillus reuteri jylb-291 improving ulcerative colitis and its application

A technology of JYLB-291, Lactobacillus reuteri, applied in the field of probiotics, can solve the problems of large differences in the human digestive system, unstable bacterial activity, short storage time, etc., and achieve significant improvement in symptoms and disease activity index. Effect

Active Publication Date: 2022-02-22
WEIFANG ZHONGKEJIAYI BIO FODDER TECH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent application CN107485625A discloses the application of Bifidobacterium bifidum WBBJ01 in the prevention and treatment of DSS-induced ulcerative colitis in mice. Stable, short storage time, and the survival rate cannot be guaranteed after entering the digestive system, so there are great limitations in application; on the other hand, the patent application only verified that Bifidobacterium bifidum WBBJ01 has the However, the human digestive system is very different from that of mice, so Bifidobacterium bifidum WBBJ01 is not necessarily applicable to ulcerative colitis in humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri jylb-291 improving ulcerative colitis and its application
  • Lactobacillus reuteri jylb-291 improving ulcerative colitis and its application
  • Lactobacillus reuteri jylb-291 improving ulcerative colitis and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Screening and Identification of Roysh Lactobacillus JYLB-291

[0023] First, the screening of strains

[0024] 1. Source:

[0025] In January 2016, Haiyang City, Yantai City, Shandong Province, China, healthy adult feces.

[0026] 2. Screening medium:

[0027] Screening medium includes the following components: protein 10.0g, beef powder 5.0g, yeast powder 4.0g, glucose 20.0 g, Tween 80 1.0 ml of hydrogen phosphate 2.0g, sodium three aquatic acetate 5.0g, Triangate of citrate 2.0 g, magnesium sulfate, magnesium sulfate, 4.05 g of tetrahydron sulfate, 15.0 g of agar, and 1000 ml of distilled water.

[0028] 3, screening method:

[0029] (1) Take 10 healthy adult feces in Haiyang City, Yantai City, Shandong Province.

[0030] (2) Take the sample under sterile conditions and diluted, diluted gradient is 10 -1 10 -2 10 -3 10 -4 10 -5 10 -6 10 -7 10 -8 .

[0031] (3) The dilution of each gradient was applied to the screening medium, and at 37 ° C for anaerobic culture ...

Embodiment 2

[0045] Example 2 Preparation of Roysh Lactobacillus JYLB-291 Products

[0046] Products were prepared according to the process of fermentation, centrifugal, embedding, lyophilized and preparations in Roysh Lactobacillus JYLB-291.

[0047] Specific steps are as follows:

[0048] (1) Cultivating the first grade of seeds: inoculation of the preserved Roysh Lactobacillus JYLB-291 into 5L activated medium, anaerobic, 37 ° C, and retained culture 24 h;

[0049] Among them, the activation medium is prepared according to the following groups: protein 胨 10.0g, beef powder 10.0g, yeast powder 5.0g, glucose 20.0 g, Tween 80 1.0 mL, seven hydrogen phosphate dihydrate 2.0g, three aqueous acetic acid Sodium 5.0g, triamate of citrate 2.0g, 0.2 g of magnesium sulfate, 4.05 g of tetrahydron sulfate, 1000ml of distilled water;

[0050] (2) Culture secondary seed: Incoocataly in 5% in the 50L activation medium, anaerobic, 37 ° C, 60R / min culture at anaerobic, 37 ° C, 60R / min culture;

[0051] (3...

Embodiment 3

[0056] Example 3 Rompermacillus JYLB-291 Torp Tolectal Digestible Liquid Capacity

[0057] (1) Preparation of artificial simulation gastric liquid: 9.5% hydrochloric acid solution 16.4 ml, diluted with distilled water, allowing its pH of 2.0, adding 10.0 g / L of gastric protease, mixing, and then filtered with 0.22 μm sterile filtration, It is currently available.

[0058] (2) Preparation of artificial simulating intestinal fluid: 300 g of dihydrogen phosphate, 500 ml of distilled water is added, and the pH is adjusted to 6.8 with 4 g / L sodium hydroxide solution to 1 L, and the salt is 0.3%, and 10.0. G / L trypsin, mixed, 0.22 μm sterile filtration, currently dispelled.

[0059] (3) Preparation of a bacterium in the method of Example 2 in accordance with the method of Example 2, the number of bacteria is 1 × 10 9 CFU / g.

[0060] (4) Determination of Roysh Lactobacillus JYLB-291 strain and CICC 6132 strain tolerate gastrointestinal digestible fluid capabilities:

[0061] Accu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to Lactobacillus reuteri JYLB‑291 for improving ulcerative colitis and its application. The Lactobacillus reuteri JYLB‑291 has been preserved in the China Microorganism Culture Collection Management Committee on June 27, 2019 General Microbiology Center, the preservation address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.18041, and the classification is named Lactobacillus reuteri Lactobacillus reuteri ; Lactobacillus reuteri JYLB‑291 can be used to prepare products for improving ulcerative colitis. Lactobacillus reuteri JYLB‑291 can effectively tolerate gastric acid and bile salts, and colonize the intestinal tract to improve the intestinal microbial flora and improve the development environment of the disease, regulate the balance of pro-inflammatory factors and anti-inflammatory factors, thus playing a role Improve the effect of ulcerative colitis.

Description

Technical field [0001] The present invention relates to the field of probiotics, and more particularly to Roysh Lactobacillus JYLB-291, which improves ulcerative colitis, and its application. Background technique [0002] Ulcerative colitis is a colon and rectal chronic non-specific inflammatory disease, ulcerative colitis is seen in any age, the most common people in 20 to 30. Ulcerative colitis can be used in drug treatment for antibacterial and anti-inflammatory and immunosuppressive therapy, commonly used drugs include aminosalicylic acid preparations, hormones, mercaptine drugs, and English. It is obvious that these drugs have been used for a long time, and the condition cannot be eradicated, and the treatment effect will usually be reduced over time. When strengthening drug treatment is no longer controlling symptoms or has acute symptoms such as large bleeding, perforation, surgery can be used, and full columns were removed, colon ileum or partial intestine. Surgical treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/747A61K9/19A61K47/26A61K47/46A61P1/04C12R1/225
CPCC12N1/20A61K35/747A61K9/19A61K47/26A61K47/46A61P1/04
Inventor 周文浩王兴民潘玉林司书锋张华磊曹维超张建伟刘红亮
Owner WEIFANG ZHONGKEJIAYI BIO FODDER TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap